Switch theme
Sign up to access all valuation multiples
Apeloa Pharmaceutical Co Ltd is a pharmaceutical company. It is engaged in research and development, manufacturing and marketing of APIs formulations and veterinary drugs. It offers products including Ofloxacin, Levofloxacin Hydrochloride, Marbofloxacin, and others.
1997
3.4K+
LTM Revenue $1.7B
LTM EBITDA $237M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Apeloa Pharmaceutical has a last 12-month revenue (LTM) of $1.7B and a last 12-month EBITDA of $237M.
In the most recent fiscal year, Apeloa Pharmaceutical achieved revenue of $1.7B and an EBITDA of $251M.
Apeloa Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Apeloa Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Profit | $422M | XXX | $398M | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | $237M | XXX | $251M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $173M | XXX | $163M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $154M | XXX | $143M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Apeloa Pharmaceutical's stock price is CNY 14 (or $2).
Apeloa Pharmaceutical has current market cap of CNY 16.4B (or $2.3B), and EV of CNY 13.7B (or $1.9B).
See Apeloa Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $2.3B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Apeloa Pharmaceutical has market cap of $2.3B and EV of $1.9B.
Apeloa Pharmaceutical's trades at 1.1x EV/Revenue multiple, and 7.6x EV/EBITDA.
Equity research analysts estimate Apeloa Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apeloa Pharmaceutical has a P/E ratio of 14.8x.
See valuation multiples for Apeloa Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | 11.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.8x | XXX | 15.9x | XXX | XXX | XXX |
| EV/FCF | 18.8x | XXX | 18.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialApeloa Pharmaceutical's last 12 month revenue growth is 9%
Apeloa Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Apeloa Pharmaceutical's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Apeloa Pharmaceutical's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Apeloa Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apeloa Pharmaceutical acquired XXX companies to date.
Last acquisition by Apeloa Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Apeloa Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Apeloa Pharmaceutical founded? | Apeloa Pharmaceutical was founded in 1997. |
| Where is Apeloa Pharmaceutical headquartered? | Apeloa Pharmaceutical is headquartered in China. |
| How many employees does Apeloa Pharmaceutical have? | As of today, Apeloa Pharmaceutical has 3.4K+ employees. |
| Is Apeloa Pharmaceutical publicy listed? | Yes, Apeloa Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Apeloa Pharmaceutical? | Apeloa Pharmaceutical trades under 000739 ticker. |
| When did Apeloa Pharmaceutical go public? | Apeloa Pharmaceutical went public in 1997. |
| Who are competitors of Apeloa Pharmaceutical? | Similar companies to Apeloa Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's current market cap is $2.3B |
| What is the current revenue of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's last 12 months revenue is $1.7B. |
| What is the current revenue growth of Apeloa Pharmaceutical? | Apeloa Pharmaceutical revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Apeloa Pharmaceutical? | Current revenue multiple of Apeloa Pharmaceutical is 1.1x. |
| Is Apeloa Pharmaceutical profitable? | Yes, Apeloa Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's last 12 months EBITDA is $237M. |
| What is Apeloa Pharmaceutical's EBITDA margin? | Apeloa Pharmaceutical's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Apeloa Pharmaceutical? | Current EBITDA multiple of Apeloa Pharmaceutical is 8.0x. |
| What is the current FCF of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's last 12 months FCF is $101M. |
| What is Apeloa Pharmaceutical's FCF margin? | Apeloa Pharmaceutical's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Apeloa Pharmaceutical? | Current FCF multiple of Apeloa Pharmaceutical is 18.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
